BioDuro’s Integrated Discovery Platform (IDD) helps clients move from target to pre-clinical candidate with speed, rigor, and confidence. At the same time, early discovery clients face a growing challenge: with more publications, patents, clinical trials, company activities, and modality innovations than ever before, how do they decide which opportunities are worth testing?

To explore how AI-driven target intelligence can support this process, we sat down with Olivier Collart, Founder of Intangia, to discuss how the platform helps teams identify, prioritize, and validate novel target, indication, and assay opportunities — and how this can complement BioDuro’s discovery capabilities.